Difference between revisions of "Blinatumomab (Blincyto)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Acute lymphocytic leukemia medications" to "Category:B-cell acute lymphoblastic leukemia medications") |
||
| Line 40: | Line 40: | ||
[[Category:Anti-CD3 antibodies]] | [[Category:Anti-CD3 antibodies]] | ||
| − | [[Category: | + | [[Category:B-cell acute lymphoblastic leukemia medications]] |
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
[[Category:Drugs FDA approved in 2014]] | [[Category:Drugs FDA approved in 2014]] | ||
Revision as of 20:36, 22 January 2018
General information
Class/mechanism: Bi-specific T-cell engager (BiTE) antibody that targets CD19 (expressed on B cells) and CD3 (expressed on T cells).[1][2][3]
Route: IV
Extravasation: no information
- Use of Blinatumomab (Blincyto) requires participation in the Blincyto Risk Evaluation and Mitigation Strategy (REMS) program.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient information may be found in the Blinatumomab (Blincyto) package insert.[1]
- Blinatumomab (Blincyto) patient drug information (Chemocare)[4]
- Blinatumomab (Blincyto) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 7/1/2014: Granted FDA Breakthrough Therapy designation "for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)."
- 12/3/2014: Granted FDA accelerated approval "for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL)."
- 7/11/2017: Granted FDA regular approval "for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children."
Also known as
- Code names: MT103, AMG 103
- Brand name: Blincyto